Earlier use of Keytruda could help some people with cervical cancer

15 March 2024
keytruda_big

More data from the Phase III KEYNOTE-A18 study have been released, showing the potential for Merck & Co’s (NYSE: MRK) best-selling cancer drug to be used in earlier treatment settings.

The data relate to use of the PD-1 inhibitor Keytruda (pembrolizumab) for people who are newly diagnosed with high-risk and locally advanced cervical cancer.

Already available for use later on in the treatment of cervical cancer, Keytruda has picked up approvals across a broad range of cancers over the years.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK

Companies featured in this story

More ones to watch >


Today's issue

Company Spotlight





More Features in Biotechnology